Sunyara Perez

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Part of HSBC Holdings Plc, HSBC Investment Bank Plc provides stock broking services. The company is based in London, UK.

Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD.

Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom.

Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA.

UltraSoC Technologies Ltd. engages in the development of debugging technology for the embedded electronic systems. It offers semiconductor IP for on-chip analytics, performance optimization, and hardware-based security. The company was founded by Stephen Karl Heeks, Andrew Brian Thomas Hopkins, and Klaus Dieter McDonald-Maier in 2006 and is headquartered in Cambridge, the United Kingdom.

IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom.

Sanofi-Aventis Groupe SA operates as a holding company, with interest in the manufacture and distribution of pharmaceutical products. The company was founded on December 19, 1995 and is headquartered in Paris, France.

Enso Ventures Ltd (Enso Ventures) is an independent venture capital firm founded in 2010 by Nikolay Danilov. The firm is headquartered in London, United Kingdom.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.

Detego Ltd. develops and distributes innovative software products for the fashion retail industry. Its products include Detego Suite, Detego InWarehousem Detego InStore, Detego InChannels, and Detego InReports. The company was founded in 2011 and is headquartered in London, the United Kingdom.

KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ.

Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY.

ACOLIN Fund Services AG engages in the distribution of domestic and foreign collective investment schemes. It also offers financial products and consulting services. The company was founded on January 31, 2018 and is headquartered in Zurich, Switzerland.

Luca Science, Inc. is a Japanese preclinical stage biopharmaceutical company that specializes in mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Luca Science is based in Chuo-ku, JP, and was founded in December 2018 by Masashi Suganuma. The company uses its platform technology to manufacture, store, and deliver innovative mitochondrial drugs to research and develop therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments. The CEO is Rick C. Tsai.

SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then.

RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.

Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases.

Hornet Therapeutics Ltd. provides immune cell metabolism and cell therapy for cancer treatment. The company is based in London, UK and was founded in 2019.

Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions.

Disruptive Capital Finance LLP (Disruptive Capital) is a private equity firm founded in 2006 by Cédriane Marie de Boucaud Truell, Edmund George Truell and Roger Le Tissiermr. The firm is headquartered in London.

MS Westfalia GmbH is a medical equipment company based in Troisdorf, Germany. MS Westfalia offers a range of medical equipment products, including anaesthesiology and ICU equipment, cleanrooms, X-ray machines, C-arms, physiotherapy and rehabilitation equipment, and more. The German company also provides training and technical support services for its equipment. MS Westfalia has won several awards for its innovative designs, including the Red Dot Award and the IF Design Award. The private company was founded in 1995, and the CEO is Eugen Kagan.